Cytoprotection-organoprotection by somatostatin: gastric and hepatic lesions

Szabó, Sándor; Usadel, K. H.

doi:10.1007/bf01945097

Cited by 84 publications

(74 citation statements)

References 17 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of somatostatin and octreotide on acute pancreatitis have been attributed to inhibition of the exocrine pancreatic functions [22, 23]. Increased hepatic and splenic reticuloendothelial system activity and modulation of the immune and cytokine responses have been noted following octreotide treatment [24], and may represent another mechanism of action, presumably a ‘cytoprotective effect’ [25, 26]. …”

Section: Discussionmentioning

confidence: 99%

Continuous Intravenous Octreotide Treatment for Acute Experimental Pancreatitis

Greenberg

Haddad²,

Kashtan³

et al. 1999

Digestion

View full text Add to dashboard Cite

Background: The efficacy of octreotide, the synthetic analogue of the hormone somatostatin, for the treatment of acute pancreatitis is controversial. Octreotide has been commonly administered in subcutaneous bolus injections; however, continuous intravenous infusion may be advantageous for acute conditions. Methods: Acute experimental pancreatitis was induced in rats by intraparenchymal injections of 1 ml 10% sodium taurocholate, and octreotide (1 µg/kg/h, dissolved in physiological solution, intravenously was started 4 h later and continuously infused for 48 h. Physiological solution infusions, in identical volumes, were used in the controls. The following parameters were examined: mortality; macroscopic and histological damage; hematocrit; plasma pH; acid-base balance; serum glucose; calcium, and amylase. Results: Octreotide treatment had a striking effect on mortality: 8.3 versus 91.6% in the treatment and control groups, respectively (p < 0.001). Octreotide also ameliorated pancreatic edema and intestinal dilatation, and had significant beneficial effects on histopathological damage and the biochemical alterations which are associated with acute pancreatitis. Conclusions: Continuous intravenous octreotide infusion is a potentially efficacious therapeutic method for acute pancreatitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Continuous Intravenous Octreotide Treatment for Acute Experimental Pancreatitis

Greenberg

Haddad²,

Kashtan³

et al. 1999

Digestion

View full text Add to dashboard Cite

show abstract

“…This effect of somatostatin may be beneficial in both preventing early recurrent bleeding from gastric ulcers and in promoting ulcer healing. There is also evidence from experimental studies that somatostatin activates blood coagulation [56] and that it is cytoprotective to the stomach and liver [57,58]. Somatostatin has also been reported to cause a rapid significant increase (26 vs. 34 mm Hg; p !…”

Section: Other Possible Gastrointestinal Effects Of Somatostatinmentioning

confidence: 99%

Drug Therapy for Non-Variceal Upper Gastrointestinal Bleeding

Jenkins¹

1999

Digestion

View full text Add to dashboard Cite

Section: Other Possible Gastrointestinal Effects Of Somatostatinmentioning

confidence: 99%

Somatostatin in the Treatment of Non-Variceal Upper Gastrointestinal Bleeding

Jenkins

Poulianos

Coraggio

et al. 1998

Dig Dis

View full text Add to dashboard Cite

The efficacies of somatostatin and octreotide have been widely studied in the control of bleeding from oesophageal varices. It has also been suggested that these drugs may be useful for the control of non-variceal upper gastrointestinal (UGI) bleeding, including that from peptic ulcers. In approximately 80% of patients presenting with non-variceal UGI bleeding, haemorrhage ceases spontaneously and does not recur. However, the remaining 20% of patients require active treatment. Results from recent studies have indicated that somatostatin is an effective treatment for the control of non-variceal UGI bleeding in high-risk patients, i.e. those in whom haemorrhage does not cease spontaneously or is likely to recur. In contrast there is no good evidence available at present to support a role for octreotide in this indication. The efficacy of somatostatin in controlling bleeding in patients with non-variceal UGI bleeding at high risk of mortality upon admission, or rebleeding following endoscopy, coupled with an excellent safety and tolerability profile, suggests that it may be a valuable therapeutic option in the management of non-variceal bleeding.

show abstract

Cytoprotection-organoprotection by somatostatin: gastric and hepatic lesions

Cited by 84 publications

References 17 publications

Continuous Intravenous Octreotide Treatment for Acute Experimental Pancreatitis

Continuous Intravenous Octreotide Treatment for Acute Experimental Pancreatitis

Drug Therapy for Non-Variceal Upper Gastrointestinal Bleeding

Somatostatin in the Treatment of Non-Variceal Upper Gastrointestinal Bleeding

Contact Info

Product

Resources

About